Cardiac Science invites Spacelabs to merge
November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143
November was a banner month for medical market consolidation, with Philips/ADAC, Cerner/ADAC, Philips/Agilent, Kodak/Lumisys, and Kodak/R2 among the more prominent deals. Now Cardiac Science has offered to buy Spacelabs Medical for about $143 million, paying $15 per share for all outstanding common stock, a 45% premium over the Nov. 13 per-share price.
Spacelabs rebuffed an offer made by Cardiac Science in mid-November, prompting Cardiac Science to publish its offer openly. The company has already acquired 320,200 shares of Spacelabs and has nominated a full slate of alternate candidates for the Spacelabs board of directors.
Cardiac Science plans to integrate its automatic defibrillation technology into Spacelabs' installed base of approximately 65,000 hospital patient monitors, according to Raymond Cohen, the company's president and CEO. Cardiac wants to accelerate the adoption of its core technology by other players in the cardiac patient monitoring market, including Philips (through its acquisition of Agilent Healthcare Solutions Group), GE Medical, Siemens, and Datex Ohmeda, by exploiting Spacelabs' customer base and its cardiac telemetry and telemedicine monitoring products.
© 2000 Miller Freeman Inc.
12/13/00, Issue # 118, page 3.
Mammography Study Compares False Positives Between AI and Radiologists in DBT Screening
May 8th 2025For DBT breast cancer screening, 47 percent of radiologist-only flagged false positives involved mass presentations whereas 40 percent of AI-only flagged false positive cases involved benign calcifications, according to research presented at the recent American Roentgen Ray Society (ARRS) conference.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.
